Diagnosis and Novel Therapies for Pediatric Solid Tumor
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Pediatric Oncology".
Deadline for manuscript submissions: 31 August 2026 | Viewed by 137
Special Issue Editors
Interests: pediatric melanoma; soft tissue sarcomas; pediatric gastrointestinal stromal tumors
Special Issues, Collections and Topics in MDPI journals
Interests: pediatric oncology; pediatric brain tumor; pediatrics cancer; pediatric cancer therapy; pediatric hematology
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
The field of new therapies for pediatric solid tumors is expanding rapidly. New diagnostic tools incorporate next-generation sequencing to better categorize specific subgroups, methylation analyses, and circulating tumor DNA to assess tumor burden and potentially predict relapse and outcome.
CAR-T cells are actively being studied in neuroblastoma and other solid malignancies. Targeted agents such as NTRK inhibitors have revolutionized treatment in pediatric patients with fusions in these genes. Antibody therapy has increased survival of patients with neuroblastoma, and better preclinical models, including, for example, the DepMap, are identifying new potential vulnerabilities in hard-to-treat diseases such as rhabdoid tumors.
This Special Issue aims to highlight the recent advances in the diagnosis and treatment of pediatric solid tumors. Both original research articles and review papers are welcome to be submitted to this Special Issue.
Dr. Alberto Pappo
Dr. Peter Hauser
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- pediatric solid tumors
- diagnosis
- targeted therapy
- immunotherapy
- sequencing
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
